CS Diagnostics(CSDX)
$0.070.00 (0.00%)
CSDX
CS Diagnostics financials statements
$0.07
At close:0.00 (0.00%)
CS Diagnostics (CSDX) Ratios
19 Followers
CS Diagnostics Ratios
CSDX's free cash flow for Q4 2025 was $-499.59M. For the 2025 fiscal year, CSDX's free cash flow was decreased by $-499.44M and operating cash flow was $6.84K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 23 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 5.61 | 1.59 |
| Quick Ratio | 5.61 | 1.59 |
| Cash Ratio | 0.45 | 1.59 |
| Solvency Ratio | 4.67 | 11.38 |
| Operating Cash Flow Ratio | 0.41 | 0.72 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 |
| Net Current Asset Value | $ 70.29K | $ 7.54K |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.00 | 1.00 |
| Debt Service Coverage Ratio | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 |
| Net Debt to EBITDA | -0.10 | 0.93 |
| Profitability Margins | ||
| Gross Profit Margin | 0.00% | 100.00% |
| EBIT Margin | 34.91% | -17.45% |
| EBITDA Margin | 34.91% | -17.46% |
| Operating Profit Margin | 34.91% | -17.46% |
| Pretax Profit Margin | 34.91% | -17.45% |
| Net Profit Margin | 34.91% | -17.45% |
| Continuous Operations Profit Margin | 34.91% | -17.45% |
| Net Income Per EBT | 100.00% | 100.00% |
| EBT Per EBIT | 100.00% | 99.99% |
| Return on Assets (ROA) | 0.01% | -0.00% |
| Return on Equity (ROE) | 0.01% | -0.00% |
| Return on Capital Employed (ROCE) | 0.01% | -0.00% |
| Return on Invested Capital (ROIC) | 0.01% | -0.00% |
| Return on Tangible Assets | 83.24% | -108.02% |
| Earnings Yield | 0.09% | -0.04% |
| Efficiency Ratios | ||
| Receivables Turnover | 2.59 | 0.00 |
| Payables Turnover | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 15.52 |
| Cash Conversion Cycle | 140.89 | 0.00 |
| Days of Sales Outstanding | 140.89 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 |
| Operating Cycle | 140.89 | 0.00 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | 0.00 | 0.00 |
| Free Cash Flow Per Share | 0.00 | -4.51 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.03 | 0.07 |
| Free Cash Flow Yield | 0.01% | -901.59% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | 1019.67 | -2518.30 |
| Price-to-Sales (P/S) Ratio | 374.87 | 439.51 |
| Price-to-Book (P/B) Ratio | 0.15 | 0.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 12115.43 | -0.11 |
| Price-to-Operating Cash Flow Ratio | 12115.43 | 5964.16 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 24.93 |
| Enterprise Value Multiple | 1073.67 | -2517.03 |
| Enterprise Value | 76.47M | 55.37M |
| EV to EBITDA | 1073.67 | -2517.03 |
| EV to Sales | 374.83 | 439.35 |
| EV to Free Cash Flow | 12114.35 | -0.11 |
| EV to Operating Cash Flow | 12114.35 | 5961.97 |
| Tangible Book Value Per Share | 0.00 | 0.00 |
| Shareholders’ Equity Per Share | 2.00 | 4.51 |
| Tax and Other Ratios | ||
| Effective Tax Rate | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 |
| Net Income Per Share | 0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 |
| SG&A to Revenue | 0.65 | 1.17 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 |
| Income Quality | 0.09 | -0.42 |
Currency in USD
